Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2017 08:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at the Jefferies 2017 London Healthcare Conference

SAN CARLOS, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
November 09, 2017 08:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting

SAN CARLOS, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
October 31, 2017 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results

SAN CARLOS, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
October 25, 2017 08:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide a Corporate Update on Tuesday, October 31, 2017

SAN CARLOS, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
October 11, 2017 17:33 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting

SAN CARLOS, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
September 25, 2017 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Closing of $57.5 Million Common Stock Public Offering

SAN CARLOS, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
September 20, 2017 18:07 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $50 Million of Common Stock

SAN CARLOS, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
September 19, 2017 16:35 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock

SAN CARLOS, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
September 13, 2017 08:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer

SAN CARLOS, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
September 11, 2017 08:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management

SAN CARLOS, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and TrakCel Ltd. today announced a partnership to build a scheduling and logistics tool that...